Monte Rosa’s stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments.
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Where Today's News Shapes Tomorrow
